Clinexpert Kft. — Clinical Trial Site

128 Registered trials

45 Currently recruiting

Organisation

Clinexpert Kft.

Location

Budapest III, Hungary

Identifier

ORG-100041039

Address

Kaszasdulo Utca 5, 1033, Hungary

Departments

-
#2066
2025,
2105: Clinexpert Obuda Egészségcentruma
2303, Clinexpert Óbuda Egészségcentruma
3302:Phase I. Clinical Trial Site
3601
44003
4709
Bugat Pal Hospital
Bugát Pál Kórház
Cardiology
Clinexpert Budapest
Clinexpert Gyógycentrum (#1)
Clinexpert Gyogycentrum( #1)
Clinexpert Kft
Clinexpert Kft.
Clinexpert Ltd. Phase I. Clinical Trial Site
Clinexpert Obuda Egeszegcentruma
Clinexpert Obuda Egeszsegcentruma
Clinexpert Óbuda Health Center
Clinic for pediatric pulmonology
Department of Dermatology
Department of Psychiatry
Department of Rheumatology
Dept of Oncology
Dermatology
Fázis 1 Vizsgálóhely
Gastroenterologia
Gastroenterology
Gasztroenterologia
Gyöngyösi Bugát Pál Kórház
n.a.
N/A
NA
NA (SMO Clinexpert Ltd)
Obstetrics and Gynecology
Óbudai Egészségcentrum
private
Site 003_NA.

Clinical trials at this site (128)

Search interface

Phase 3 Study Assessing Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit) Not authorised

2022-501535-16-00 Atopic Dermatitis (AD) 5
A trial to learn how well Dato-DXd and rilvegostomig work and how safe they are in participants with stage I adenocarcinoma non-small cell l… Pending

2024-512195-35-00 Stage I adenocarcinoma non-small cell lung cancer (NSCL 5
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants with Moderate-to-Severe Atopic Dermatitis (ADAPTIVE) Pending

2024-520117-50-00 Atopic Dermatitis 4
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
A Phase 3 Study of Orelabrutinib in Non-active Secondary Progressive Multiple Sclerosis Pending

2025-524322-18-00 Non-active Secondary Progressive Multiple Sclerosis (SP 5
A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Recruiting

2025-524316-11-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2026-06-11
Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Recruiting

2024-519994-20-00 Agitation Associated with Alzheimer’s Disease 5 2026-06-01
A study to assess the efficacy and safety of empasiprubart in adults with CIDP Recruiting

2025-520805-10-00 Chronic inflammatory demyelinating polyneuropathy (CIDP 5 2026-03-12
A study to assess efficacy and safety of empasiprubart versus IVIg in adults with CIDP ("emvigorate") Recruiting

2024-520097-36-00 Chronic inflammatory demyelinating polyneuropathy (CIDP 5 2026-01-07
A Long-Term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older with Moderate to Severe Eczema Recruiting

2023-509124-18-00 Moderate-to-Severe Atopic Dermatitis 5 2025-12-19
A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Ad… Recruiting

2025-521240-37-00 Major Depressive Disorder (MDD), with or without Anxiou 4 2025-09-11
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with… Recruiting

2024-513965-38-01 Sjögren's Disease 5 2025-06-16
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w… Recruiting

2023-507853-13-00 Ulcerative Colitis 4 2025-02-25
Study of GS-1427 in Participants With Moderately to Severely Active UC Recruiting

2023-508304-38-00 Ulcerative Colitis (UC) 4 2024-09-10
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participant… Recruiting

2023-505678-14-00 Ulcerative Colitis 4 2024-08-19
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with a… Recruiting

2023-509606-30-00 Ulcerative colitis 5 2024-07-24
Long-term Extension Study to Assess Adverse Events and Tolerability of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Ag… Recruiting

2022-501099-24-00 Migraine 5 2023-12-22
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) … Recruiting

2022-501100-94-00 Episodic Migraine 5 2023-11-08
A phase 2, multicenter, double-blind, two-arm study of subcutaneous RO7790121 for the treatment of subjects with moderate to severe active c… Recruiting

2023-504265-23-00 Crohn's disease 4 2023-10-23
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight and Diabetes Recruiting

2025-523510-87-00 Obesity 5 2026-06-25
Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting

2023-503766-24-00 Moderate to Severe Plaque Psoriasis 11 2026-05-26
EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting

2025-523975-48-00 Obesity 5 2026-05-08
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting

2025-521546-23-00 Secondary progressive multiple sclerosis 5 2026-04-21
A study to learn if galvokimig is safe and works in adults with moderate to severe atopic dermatitis Recruiting

2025-522578-35-00 Atopic Dermatitis 4 2026-03-30